In this edition of Biotech Banter, Motley Fool contributor Brian Orelli and health care bureau chief Max Macaluso discuss an FDA delay for MannKind's Afrezza, clinical trial results from Amgen's T-VEC, up-and-coming biotech Agios, and the biotech "Tweet of the Week."

The 9-minute dividend strategy you need to know
One of the dirty secrets that few finance professionals will openly admit is the fact that dividend stocks as a group handily outperform their non-dividend paying brethren. The reasons for this are too numerous to list here, but you can rest assured that it's true. However, knowing this is only half the battle. The other half is identifying which dividend stocks in particular are the best. With this in mind, our top income analyst put together a report outlining a simple 9-minutes-a-year dividend strategy that should be in every income investor's toolkit. To learn more about this "tax-skipping" dividend trick, all you have to do is click here now.

Brian Orelli has no position in any stocks mentioned. Max Macaluso, Ph.D. owns shares of Celgene. The Motley Fool recommends Celgene. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Compare Brokers